Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.61 -1.6%	$9.28	$6.38 ▼ $17.30	$929.66M	1.42	1.23 million shs	760,168 shs
COGT Cogent Biosciences	$10.98 +1.2%	$6.54	$3.72 ▼ $12.61	$1.25B	1.88	1.57 million shs	3.39 million shs
MNPR Monopar Therapeutics	$36.87 -3.6%	$35.55	$1.72 ▼ $54.30	$225.47M	1.01	362,872 shs	40,442 shs
OCS Oculis	$18.06 -1.8%	$18.95	$10.79 ▼ $23.08	$788.54M	0.29	45,600 shs	24,376 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	0.00%	+7.68%	+2.89%	+25.13%	-40.38%
COGT Cogent Biosciences	0.00%	+44.19%	+52.08%	+157.75%	+23.23%
MNPR Monopar Therapeutics	0.00%	+2.79%	+9.02%	+5.67%	+947.44%
OCS Oculis	0.00%	-4.72%	-8.23%	+7.82%	+61.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	1.8028 of 5 stars	3.5	1.0	1.5	1.7	0.6
COGT Cogent Biosciences	3.0254 of 5 stars	4.4	3.0	2.4	0.0	0.6
MNPR Monopar Therapeutics	2.0279 of 5 stars	3.4	2.0	2.7	1.7	0.0
OCS Oculis	2.0512 of 5 stars	3.5	3.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	89.04% Upside
COGT Cogent Biosciences	2.82	Moderate Buy	$18.00	63.93% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	62.73% Upside
OCS Oculis	3.00	Buy	$35.33	95.64% Upside

Current Analyst Ratings Breakdown

Latest MNPR, AVDL, COGT, and OCS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/8/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $22.00
7/8/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/8/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
7/7/2025	COGT Cogent Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $28.00
7/7/2025	COGT Cogent Biosciences	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/30/2025	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/17/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/29/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$21.00 ➝ $25.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	5.50	N/A	N/A	$0.77 per share	12.48
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
OCS Oculis	$780K	1,010.90	N/A	N/A	$1.91 per share	9.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	160.17	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)
OCS Oculis	-$97.43M	-$2.64	N/A	N/A	N/A	-13,788.70%	-92.95%	-70.03%	8/26/2025 (Estimated)

Latest MNPR, AVDL, COGT, and OCS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	N/A	MNPR Monopar Therapeutics	-$0.47	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.54	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/8/2025	Q1 2025	OCS Oculis	-$0.51	-$0.77	-$0.26	-$0.77	$0.22 million	$0.32 million
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
COGT Cogent Biosciences	N/A	5.13	5.13
MNPR Monopar Therapeutics	N/A	36.91	36.91
OCS Oculis	N/A	4.79	4.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
COGT Cogent Biosciences	N/A
MNPR Monopar Therapeutics	1.83%
OCS Oculis	22.30%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
COGT Cogent Biosciences	7.29%
MNPR Monopar Therapeutics	20.50%
OCS Oculis	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable

MNPR, AVDL, COGT, and OCS Headlines

Recent News About These Companies

Oculis (NASDAQ:OCS) Stock Price Down 1.1% - What's Next?

July 10 at 3:54 AM | marketbeat.com

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

July 9, 2025 | globenewswire.com

OCS - Oculis Holding AG Executives - Morningstar

July 5, 2025 | morningstar.comM

Oculis Holding AG (OCS) - Yahoo Finance

June 28, 2025 | sg.finance.yahoo.com

Oculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short Interest

June 17, 2025 | marketbeat.com

Oculis Publishes Results of 2025 Annual General Meeting

June 5, 2025 | globenewswire.com

Oculis Publishes Results of 2025 Annual General Meeting

June 5, 2025 | globenewswire.com

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

June 3, 2025 | globenewswire.com

Oculis to Participate in Upcoming June Investor Conferences

June 3, 2025 | markets.businessinsider.com

Oculis Holding AG Announces Participation in Upcoming Investor Conferences in June 2025

June 3, 2025 | quiverquant.comQ

Oculis to Participate in Upcoming June Investor Conferences

June 3, 2025 | globenewswire.com

Oculis to Participate in Upcoming June Investor Conferences

June 3, 2025 | globenewswire.com

Oculis Holding AG: Oculis Reports Q1 Financial Results and Provides Company Update

May 11, 2025 | finanznachrichten.de

Oculis Publishes Invitation to the Annual General Meeting

May 9, 2025 | globenewswire.com

Oculis Publishes Invitation to the Annual General Meeting

May 9, 2025 | globenewswire.com

Oculis posts widening quarterly loss as R&D spend climbs

May 9, 2025 | thepharmaletter.comT

Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Oculis Reports Q1 Financial Results and Provides Company Update

May 8, 2025 | globenewswire.com

Oculis Reports Q1 2025 Financial Results and Provides Company Update

May 8, 2025 | globenewswire.com

Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline

May 7, 2025 | zacks.com

Oculis to Present at Upcoming May Investor Conferences

May 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR, AVDL, COGT, and OCS Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.61 -0.16 (-1.64%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$9.46 -0.15 (-1.51%)

As of 07/11/2025 05:47 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Cogent Biosciences NASDAQ:COGT

$10.98 +0.13 (+1.20%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$11.04 +0.06 (+0.55%)

As of 07/11/2025 07:59 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Monopar Therapeutics NASDAQ:MNPR

$36.87 -1.39 (-3.63%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$36.74 -0.13 (-0.35%)

As of 07/11/2025 04:04 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Oculis NASDAQ:OCS

$18.06 -0.34 (-1.85%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$18.02 -0.04 (-0.22%)

As of 07/11/2025 04:04 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time